ALX Oncology Holdings, Inc. (ALXO)
1.17
-0.02
(-1.68%)
USD |
NASDAQ |
Oct 23, 16:00
1.17
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Net Income (Quarterly) : -17.97M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.97M |
| March 31, 2026 | -17.93M |
| December 31, 2025 | -22.85M |
| September 30, 2025 | -22.14M |
| June 30, 2025 | -25.95M |
| March 31, 2025 | -30.75M |
| December 31, 2024 | -29.16M |
| September 30, 2024 | -30.71M |
| June 30, 2024 | -39.40M |
| March 31, 2024 | -35.58M |
| December 31, 2023 | -45.47M |
| September 30, 2023 | -50.99M |
| June 30, 2023 | -34.16M |
| March 31, 2023 | -30.18M |
| December 31, 2022 | -30.71M |
| Date | Value |
|---|---|
| September 30, 2022 | -35.32M |
| June 30, 2022 | -32.92M |
| March 31, 2022 | -24.53M |
| December 31, 2021 | -28.44M |
| September 30, 2021 | -24.57M |
| June 30, 2021 | -16.27M |
| March 31, 2021 | -14.18M |
| December 31, 2020 | -18.77M |
| September 30, 2020 | -10.18M |
| June 30, 2020 | -11.33M |
| March 31, 2020 | -5.454M |
| December 31, 2019 | -7.764M |
| September 30, 2019 | -3.044M |
| June 30, 2019 | -4.197M |
| March 31, 2019 | -4.238M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 17.97M |
| EPS Diluted (Quarterly) | -0.1325 |
| Enterprise Value | 34.52M |
| Earnings Yield | -97.27% |
| Normalized Earnings Yield | -96.98 |